- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06209281
A Phase III Clinical Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops (Mini-CHAMP)
A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase III Clinical Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops in Slowing the Progression of Myopia in Children
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Eligible subjects were screened and randomly assigned to the placebo control group, the lower dose group, and the lower dose group. Subjects received the study drug in both eyes, 1 drop each time, once every night before sleep, for continuous administration.A total of 526 subjects were planned to be enrolled。
Statistical analyses were performed with the use of SAS software, version 9.4, without any specific description. All statistical tests were two-sided at a 0.05 level.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China
- Eye & ENT Hospital of Fudan University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Child (female or male) aged 6 to 10 years.
- Myopia (SER of at least -0.50 D and no more myopic than -6.00 D) in each eye as measured by cycloplegic autorefraction.
- If present, astigmatism of ≤1.50 D in each eye as measured by cycloplegic autorefraction.
- Anisometropia SER of < 1.50 D as measured by cycloplegic autorefraction.
Exclusion Criteria:
- History of any disease or syndrome that predisposed the subject to severe myopia (e.g.,Marfan syndrome, Stickler syndrome, retinopathy of prematurity).
- History in either eye of abnormal ocular refractive anatomy (e.g., keratoconus, lenticonus,spherophakia).
Chronic use of any topical or systemic antimuscarinic/anticholinergic medications (e.g.,atropine, scopolamine, tropicamide) within 21 days prior to screening and/or anticipated need for chronic use during the study period (i.e., more than 7 consecutive days in 1 month or more than 30 total days in 1 year).
Use of cycloplegic drops for dilated ocular exam was allowable.
- Heart rate persistently (for more than 10 minutes) > 120 beats per minute.
- Allergy to study drugs.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental group 1
1 drop each time, once every night at bedtime
|
Administer to eyes
Other Names:
Administer to eyes
Other Names:
|
Experimental: Experimental group 2
1 drop each time, once every night at bedtime
|
Administer to eyes
Other Names:
|
Experimental: control group
1 drop each time, once every night at bedtime
|
Administer to eyes
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cycloplegic Autorefraction(low)
Time Frame: twelve months
|
Group difference in the proportion of subjects eyes with myopia progression (SER) less than -0.50 D at M12 visit with low atropine versus placebo.
|
twelve months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cycloplegic Autorefraction(lower)
Time Frame: twelve months
|
Group difference in the proportion of subjects eyes with myopia progression (SER) less than -0.50 D at M12 visit with lower atropine versus placebo.
|
twelve months
|
Cycloplegic Autorefraction(SER)
Time Frame: twelve months
|
Between-group difference in the mean change from baseline in SER at visit M12
|
twelve months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Axial Length
Time Frame: twelve months
|
Between-group difference in the mean change from baseline in axial length at visit M12
|
twelve months
|
Crystalline Lens Thickness
Time Frame: twelve months
|
Between-group difference in the mean change from baseline in crystalline lens thickness at visit M12
|
twelve months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Xiaomei Qu, Eye & ENT Hospital of Fudan University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Eye Diseases
- Refractive Errors
- Myopia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Parasympatholytics
- Autonomic Agents
- Peripheral Nervous System Agents
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Adjuvants, Anesthesia
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Pharmaceutical Solutions
- Mydriatics
- Ophthalmic Solutions
- Atropine
Other Study ID Numbers
- ZKO-ATP-202105-Mini-CHAMP
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myopia
-
He Eye HospitalNot yet recruiting
-
University of BradfordCoopervision, Inc.; University of HuddersfieldNot yet recruiting
-
Visioneering Technologies, IncRecruitingMyopiaUnited States, Canada, Hong Kong, Singapore
-
University Eye Hospital, FreiburgRecruiting
-
Shanghai 10th People's HospitalCompletedMyopia | Myopia, ProgressiveChina
-
Tianjin Eye HospitalActive, not recruiting
-
Tianjin Eye HospitalCompleted
-
Sultan Qaboos UniversityChristian Medical College, Vellore, IndiaUnknown
-
Peking University People's HospitalUnknownProgressive MyopiaChina
-
Shanghai Eye Disease Prevention and Treatment CenterNot yet recruiting
Clinical Trials on Lower dose atropine sulfate eye drops
-
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical...Active, not recruiting
-
Fovea Pharmaceuticals SACompletedDiabetic Macular EdemaUnited States, Australia, Belgium, Czech Republic, France, Germany, Israel, Italy, Poland, Spain
-
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical...CompletedCorneal Epithelial DefectChina
-
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical...CompletedCorneal Epithelium DefectChina
-
Alcon ResearchCompleted
-
Hai Yen Eye CareBrien Holden VisionCompleted
-
TRB Chemedica International SANot yet recruiting
-
TRB Chemedica International SANot yet recruiting
-
University of RochesterBausch & Lomb IncorporatedCompleted
-
University Eye Hospital, FreiburgRecruiting